Advancements in Understanding Inherited Cardiomyopathies through Massive Parallel DNA Sequencing

Emin Karaca^*
*Correspondence: Emin Karaca, Department of RNA Biology, University of Galway, University Rd, Galway, Ireland, Email:

Introduction

Inherited cardiomyopathies represent a heterogeneous group of genetic disorders characterized by abnormal heart muscle structure and function. These conditions pose a significant burden on affected individuals and their families due to their diverse clinical presentations and potential for sudden cardiac death. While traditional diagnostic approaches rely on clinical evaluation and imaging techniques, recent advancements in molecular genetics, particularly massive parallel DNA sequencing, have revolutionized our understanding of these diseases. This article explores the utility of MPS in diagnosing inherited cardiomyopathies, its impact on clinical management, challenges, and future directions.

Inherited cardiomyopathies encompass hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, and restrictive cardiomyopathy. These conditions result from mutations in genes encoding sarcomeric, cytoskeletal, or myocardial structure proteins, leading to impaired cardiac function [1-3]. The clinical phenotype varies widely, ranging from asymptomatic individuals to heart failure, arrhythmias, and sudden cardiac death. Historically, diagnosing inherited cardiomyopathies relied on clinical evaluation, electrocardiography, echocardiography, and familial history. However, these methods often lack sensitivity and specificity, especially in identifying the underlying genetic cause. Additionally, phenotypic overlap between different cardiomyopathy subtypes further complicates accurate diagnosis.

Description

Massive parallel DNA sequencing, including Next-Generation Sequencing (NGS) technologies, has transformed the diagnostic approach to inherited cardiomyopathies. By simultaneously analyzing multiple genes associated with these conditions, MPS offers a comprehensive and efficient method for identifying disease-causing mutations. Targeted gene panels, Whole-Exome Sequencing (WES), and Whole-Genome Sequencing (WGS) are common MPS strategies employed in clinical practice. MPS has substantially increased the diagnostic yield in inherited cardiomyopathies, enabling precise genetic diagnosis in a significant proportion of cases. Identification of pathogenic variants not only facilitates accurate disease classification but also guides risk stratification, prognostication, and personalized management strategies. Furthermore, genetic testing informs family screening and cascade testing, aiding in early detection and intervention among at-risk relatives.

Despite its advantages, MPS presents several challenges in the clinical context. Interpretation of genetic variants, particularly variants of uncertain significance, requires careful consideration of clinical and functional data to assess pathogenicity accurately. Moreover, cost constraints, insurance coverage, and the availability of specialized expertise may limit widespread adoption of MPS, especially in resource-limited settings. Ethical considerations regarding incidental findings and patient autonomy also warrant attention in genetic testing practices [4,5].

Continued advancements in sequencing technologies, bioinformatics tools, and data interpretation algorithms hold promise for further enhancing the utility of MPS in inherited cardiomyopathies. Integration of multi-omics data, including transcriptomics, proteomics, and metabolomics, may provide comprehensive insights into disease pathogenesis and individualized treatment strategies. Collaborative efforts to establish large-scale genomic databases and international consortia can facilitate genotype-phenotype correlations, gene discovery, and therapeutic target identification.

Conclusion

Massive parallel DNA sequencing represents a paradigm shift in the diagnosis and management of inherited cardiomyopathies. By elucidating the genetic basis of these diseases, MPS enables personalized approaches to patient care, improves risk stratification, and facilitates early intervention to prevent adverse outcomes. Despite challenges, ongoing research and technological innovations promise to further refine our understanding of inherited cardiomyopathies and optimize clinical outcomes for affected individuals and their families.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Maron, Barry J., Jeffrey A. Towbin, Gaetano Thiene and Charles Antzelevitch, et al. "Contemporary definitions and classification of the cardiomyopathies: An American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention." Circulation 113 (2006): 1807-1816.

Google Scholar, Crossref, Indexed at

2. Bezzina, Connie R., Najim Lahrouchi and Silvia G. Priori. "Genetics of sudden cardiac death." Circ Res 116 (2015): 1919-1936.

Google Scholar, Crossref, Indexed at

3. Geisterfer-Lowrance, Anja AT, Susan Kass and Gary Tanigawa. "A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation." Cell 62 (1990): 999-1006.

Google Scholar, Crossref, Indexed at

4. Seidman, Christine E. and J. G. Seidman. "Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: A personal history." Circ Res 108 (2011): 743-750.

Google Scholar, Crossref, Indexed at

5. Teekakirikul, Polakit, Wenjuan Zhu, Helen C. Huang and Erik Fung. "Hypertrophic cardiomyopathy: An overview of genetics and management." Biomolecules 9 (2019): 878.

Google Scholar, Crossref, Indexed at